Kornimate/medical-research-clean huggingface dataset:
multi-family group therapy for reducing behavioral difficulties in youth

Conditions: Oppositional Defiant Disorder; Conduct Disorder

Summary: this study will examine the effectiveness of a multiple family group mental health service delivery strategy in improving mental health service use and outcome for urban, low income children of color, ages 7-11 years old with disruptive behaviors and their families.

oppositional defiant disorder (odd) and conduct disorder (cd) are two common childhood psychiatric disorders. children with odd frequently have temper tantrums, argue excessively with adults, deliberately attempt to annoy or upset people, and blame others for their mistakes or behavior. children with cd may exhibit aggression toward people and animals, destruction of property, deceitfulness, and rule breaking. the symptoms of these disorders can negatively affect children's social, family, and academic lives. research has shown that early, comprehensive treatment leads to better treatment outcomes. both disorders are commonly treated using parent training techniques. a multiple family group therapy setting may prove to be more engaging and beneficial than standard care for both parents and children. this study will examine the effectiveness of a multiple family group (mfg) mental health service delivery strategy in improving mental health service use and treatment outcome for urban, low income children of color with odd or cd. participants in this 18-month, open-label study will be randomly assigned to either receive standard of care or participate in an mfg in addition to receiving standard of care. participants assigned to standard of care will receive treatment that is traditionally offered to outpatients. participants in an mfg will meet in their groups once a week for 16 weeks. sessions will include adult caregivers and all children over age 6. each session will follow the same procedures, and will proceed through the following stages: creating social networks; information exchange; group discussions; individual family practice; and homework assignment. assessments of youth functioning will be held at weeks 8 and 16 and months 6 and 18 post-treatment.

Eligibility criteria:
inclusion criteria: * youth participants are between the ages of 7 and 11 * adult caregivers are available to participate in the research and intervention activities * both youth and adult caregiver are english- or spanish-speaking * youth meets criteria for a primary diagnosis of oppositional defiant disorder or conduct disorder, as measured by the disruptive behavior disorder rating scale (dbd) exclusion criteria: * youth has significant cognitive impairment that might interfere with understanding of program content or informed consent process * youth or adult has emergency psychiatric needs that require services beyond those provided within an outpatient setting (e.g., hospitalization or specialized placement outside the home) * youth who are wards of the state

Keywords: oppositional defiant disorder
low anterior resection syndrome after rectum resection for rectal carcinoma.

Conditions: Low Anterior Resection Syndrome; Quality of Life; Incontinence

Summary: the aco-asso (austrian society of surgical oncology) colorectal group and austrian working group for coloproctology present the lars austria study. it is a prospective, multicenter observational study. the primary objective of this study is to collect information about lars (lars score) and qol (eortc -cr29) in patients with non-metastatic rectal cancer who received therapy. as a secondary objective, the impact of radiotherapy on the occurrence of lars will be investigated.

all consecutive patients with biopsy verified rectal cancer (≤16cm from anocutaneous line) can be included in the study. for the study, tumors whose aboral margin, when measured with a rigid rectoscope, is 16 cm or less from the anocutaneous line will be included. thus, only histologically verified tumors of the lower (\<6 cm), middle (6\<12 cm) and upper (12-16cm) rectal thirds are included. patients will be included after the indication for further therapy has been established in the tumor board according to guideline criteria and after signing the participation consent. the collection of study relevant data will be performed according to the following scheme: group 1 = patients without neoadjuvant radiochemotherapy (rcht). collection of data and questionnaires before surgery and 3, 6, and 12 months after index surgery (if no protective stoma). or collection of data and questionnaires before surgery and 3, 6, or 12 months after stoma re-operation (if protective stoma). group 2 = patients with neoadjuvant rcht/ definitive rcht=watch and wait. collection of data and questionnaires before rcht and before surgery or after rcht and 3, 6, or 12 months after index surgery (if no protective stoma). or collection of data and questionnaires before rcht and before operation=surgery(op) or after rcht and 3, 6 or 12 months after stoma closure (if protective stoma) or collection of data and questionnaires before rcht and 3, 6 and 12 months after rcht (if no surgery)

Eligibility criteria:
inclusion criteria: * age: 18 to 99 years * patients with biopsy-verified rectal cancer. * patients scheduled for elective sphincter-preserving rectal surgery * patients scheduled for neoadjuvant rctx (chemo-radiation) (concept: short course radiation, conv. fractionated rctx, total neoadjuvant therapy(tnt)) * signed consent (icf) exclusion criteria: * patients younger than 18 years * patients without signed informed consent * metastatic carcinoma * terminal colostomy ( apr (abdominoperineal resection),...)
prophylactic antibiotics after functional endoscopic sinus surgery: a randomized, double-blind placebo controlled trial

Conditions: Sinusitis

Summary: surgeons commonly prescribe post operative prophylactic antibiotics after sinus surgery. there is minimal data to support this. the investigators' study will aim to demonstrate that patients' quality of life and rate of post operative infection is the same whether they receive or do not receive antibiotics post operatively. the investigators hypothesis is that the disease specific quality of life of patients taking post-operative antibiotics is not inferior to the quality of life of patients who do not take post-operative antibiotics, and the rate of post-operative infections are the same. the investigators' specific aim is to compare validated symptom scores between post-operative populations who are given or are not given antibiotics. rates of infections in the first 10 days after surgery will be recorded. the investigators will also compare endoscopic grades of sinus cavities during the post-operative follow up exams as an additional outcome measure.

functional endoscopic sinus surgery (fess) is a commonly performed procedure in the united states to treat chronic rhinosinusitis. common practice is to prescribe prophylactic antibiotics postoperatively. this is similar to the long tradition of prophylactic antibiotics after tonsillectomy. the american academy of otolaryngology - head and neck surgery recently strongly recommended against prophylactic antibiotics after tonsillectomy. in this light, this study would demonstrate the lack of need for antibiotics after fess. currently one surgeon does not prescribe antibiotics except when evidence of active infection was found during surgery. the other surgeon in the study currently prescribes antibiotics. this study would prospectively compare the two groups in a randomized fashion. the investigators' plan to use the sinonasal outcomes test - 22 (snot-22) as the investigators' primary outcomes measure, which is a validated quality of life instrument in sinusitis.

Eligibility criteria:
inclusion criteria: - patients eligible for surgery would be patients with chronic rhinosinusitis (defined by the aaohns 2007 consensus statement by rosenfeld et al) and have been determined by their surgeons to have persistent symptoms after maximal medical therapy. maximal medical therapy is defined as a course of broad spectrum or culture-directed antibiotics used in conjunction with a nasal steroid. exclusion criteria: 1. penicillin, cephalosporin, amoxicillin/clavulanate allergy 2. cystic fibrosis 3. immunodeficiency 4. presence of any foreign body (ie.absorbable and non-absorbable packing) after surgery 5. odontogenic causes of sinusitis 6. fungal ball 7. infected mucocele 8. complication of sinusitis (meningitis, orbital complication, cellulitis, brain abscess) 9. non endoscopic sinus surgery (caldwell luc, external approaches, etc) 10. age \<18 11. pregnant women

Keywords: chronic rhinosinusitis sinus surgery antibiotics
study to evaluate the impact of difficult to treat sites on biological response in moderate-to-severe plaque psoriasis(pso).

Conditions: Plaque Psoriasis

Summary: this study is to evaluate available local data in iraq patients with moderate-to-severe plaque psoriasis on enbrel treatment with regards to efficacy, treatment for pso who have difficult to treat sites at presentation.


Eligibility criteria:
inclusion criteria: * moderate-to-severe plaque psoriasis patients whom have been receiving etanercept for at least 1 year duration. * have difficult to treat sites at presentation. * age ≥18 years. * no history of using other biological treatments, other than etanercept for the treatment of moderate-to-severe pso. exclusion criteria: * etanercept use for treatment of moderate-to-severe pso less than 1 year duration. * previous use of another biological treatment for treatment of moderate-to-severe pso.
effect of non-surgical periodontal treatment and c-reactive protein levels in hemodialysis patients

Conditions: Chronic Kidney Disease Stage 5; Periodontitis

Summary: the presence of periodontitis has been hypothesized as a risk factor for several systemic outcomes, including chronic kidney disease (ckd). therefore, the aim of this study is to evaluate the impact of non-surgical periodontal treatment on crp levels and quality of life of patients with chronic kidney disease undergoing hemodialysis (hd) in santa maria-rs.

c-reactive protein (crp) has been identified as a possible mediator of the association between periodontitis and various systemic diseases. the presence of periodontitis has been hypothesized as a risk factor for several systemic outcomes, including chronic kidney disease (ckd). therefore, the aim of this study is to evaluate the impact of non-surgical periodontal treatment on crp levels and quality of life of patients with chronic kidney disease undergoing hemodialysis (hd) in santa maria-rs. a total of 88 patients with severe periodontitis who are on hd therapy will be included in this study. at baseline, periodontal, radiographic, blood test, and quality-of-life questionnaire will be assessed for all patients, after which severe periodontitis will be defined according to the american association of periodontology and european federation of periodontology. the 88 patients with periodontal disease will be randomized and divided into two groups. one group will receive full mouth non-surgical periodontal treatment (tpnc) and a late treatment group that will receive tpnc only at the end of the study. all patients will receive follow-up of periodontal parameters and blood collection for initial crp assessment at 3 and 6 months after treatment. outcome evaluators will be blind to the group the patient belongs to. patients in the immediate treatment group will receive follow-up oral hygiene instructions and use 0.12% chlorhexidine mouthwash during the first week after treatment.

Eligibility criteria:
minimum age: 18 years sex: all accepts healthy volunteers: no criteria: inclusion criteria: * having been diagnosed with chronic kidney disease (ckd) for at least 90 days. * have at least 8 teeth in the mouth. * for the patient to be classified as having periodontal disease, he must have at least two nonadjacent sites with insertion loss of 3mm or more and two nonadjacent sites with probing depth of 4mm or more. exclusion criteria: ineligible individuals were characterized by exhibiting one of the following conditions: * patients diagnosed with malignant neoplasia; * patients diagnosed with carriers of the hiv virus; * pregnant or lactating women; * patients with absence of all dental elements (total edentulous); * patients undergoing orthodontic treatment; * patients who have received periodontal treatment in the last 6 months. * patients with active infection (other than periodontitis) who require antibiotic prophylaxis;

Keywords: chronic kidney disease hemodialysis periodontal diseases periodontitis
clinical trial of new intermittent single-use catheter

Conditions: Urinary Incontinence

Summary: a multi-centre, open-labelled, randomised, crossover design. the total study duration for the individual subject will be approximately 4 weeks, consisting of four site visits and two 2-week test periods at home. visits 0 and 1 can be performed on the same day. for visit 2 and 3, 2 catheterisations will be performed in a hospital setting (one hcp catheterisation and one self-catheterisation) for bladder emptying and user experience assessments. visit 1 and 2 are followed by a home-use test period, followed by visit 3 which terminates the study.


Eligibility criteria:
inclusion criteria: * is female * is at least 18 years of age and has full legal capacity * has signed an informed consent form * has used clean intermittent self-catheterisation (cisc) (ch12 or ch14) for at least one month up to inclusion * is using intermittent self-catheterisation for a minimum of 3 times per day for bladder emptying * has used a compact catheter 50% of the time (or more) for the last two weeks prior to entering the study * has the ability (assessed by investigator) and willingness to follow study procedures exclusion criteria: * is participating in any other clinical study during this investigation * has previously participated in this study * has symptoms of urinary tract infection at time of inclusion, as judged by the investigator (if the patient recovers within the recruitment period, a second inclusion is allowed, under a different subject id) * is an individual with a history of - suspected to be - or showing signs of producing an excessive amount of mucus or large/clustered sediments or debris * has any known allergies towards ingredients in the investigational device * is pregnant * is breastfeeding
burden of new onset atrial fibrillation in patients with acute myocardial infarction

Conditions: Atrial Fibrillation New Onset; Acute Myocardial Infarction

Summary: to validate the prognostic importance of the burden of new-onset atrial fibrillation (noaf) complicating acute myocardial infarction (ami) in a prospectively designed hospital-based registry. to characterize those factors that contribute to the progression of post-mi noaf burden. to establish a prediction model for the risk stratification of patients with noaf complicating ami. to explore the clinical usefulness of noaf burden in guiding the anticoagulation therapy among patients with post-mi noaf.

our previously designed single-center retrospective cohort study (nct03533543) suggested that patients with a greater burden of noaf complicating ami were challenged by a poor prognosis. in the present study, we aim to design a multicenter, prospective, hospital-based registry to validate the preceding findings. we plan to enroll patients who were admitted for ami in 9 tertiary medical centers from shanghai, henan, and zhejiang provinces and developed noaf during the index hospitalization. all eligible patients' demographics, cardiovascular risk factors, comorbidities, laboratory tests, echocardiography data, angiography data, and medications will be collected. noaf burden is calculated by dividing the total af duration by the total continuous electronic monitoring (cem) duration. other noaf related characteristics, such as af pattern, af frequency, and symptomatic or silent af, and the longest af episode duration will also be evaluated. all patients who are discharged alive will be followed for at least 2 years and cardiovascular outcomes will be recorded.

Eligibility criteria:
inclusion criteria: * adult patients (\>18 years old); * patient with ami (including stemi and nstemi) who developed noaf during the index hospitalization; * patients must have received in-hospital cem for at least 5 days; * patients must give informed consent. exclusion criteria: * patients with a medical history of pre-existing af; * patients with a medical history of rheumatic valvular disease; * patients with a medical history of sick sinus syndrome; * patients undergoing emergent coronary artery bypass surgery; * patients who suffer malignant tumors with an expected lifetime less than 1 year ; * patients who refuse to receive cem during hospitalization and the data of heart rhythm cannot be retrieved; * patients who refuse to receive percutaneous coronary intervention (pci) or have contraindications for pci; * patients who have died during the index hospitalization.

Keywords: acute myocardial infarction new-onset atrial fibrillation burden prospective cardiovascular outcomes
antibiotic stewardship to prevent early sepsis in preterm infants

Conditions: Prematurity, Infections

Summary: early onset sepsis (eos) occurs in newborns within the first 72 hours of life, and is rare, about 0.8 cases per 1000 births (1). it is more frequent in premature infants and potentially more severe (as much as 75% of deaths has been reported in extreme premature infants (1)). infection is considered as confirmed when blood or cerebral fluid cultures detect a pathogen (1). it is considered probable when cultures are negative, but there are clinical (fever, hemodynamic failure, severe respiratory condition) and biological (inflammatory markers) signs suggestive of infection. in 2017, french recommendations for prevention of eos in term and near-term infants has been proposed. however, to date, there are no recommendations for the population of premature newborns, and there are discrepancies in practices antibiotic stewardship to prevent early sepsis in infants born before 35 weeks. preterm infants are more exposed to eos than infants born closer to term. the incidence is inversely proportional to gestational age, reaching 32 cases per 1000 births in infants born between 22 and 24 weeks. infection is a major cause of mortality and morbidity in premature newborns, because of the immaturity of their immune system. the death rate reach 50% in infants born between 22 and 28 weeks. for these reasons, probabilistic antibiotic therapy is prescribed at admission in neonatology in 35 to 50% of very premature babies. but it appears that the prescription of antibiotics is not correlated with the incidence of eos, with overuse of antibiotics, related to the fear of infection in these fragile patients. however, exposure to antibiotics induces gut dysbiosis, which is the main risk factor of necrotizing enterocolitis, a potentially severe disease occurring specifically in preterm infants. it is therefore important to optimize antibiotic stewardship in the days following birth, to improve the quality of care. to this end, we shall analyse antibiotic prescription practices and the rate of eos in premature newborns hospitalized in a tertiary care unit at the croix rousse university hospital.


Eligibility criteria:
inclusion criteria: * - infants born at a gestational age of less than 35 weeks - born between january 1, 2021 and december 31, 2023 exclusion criteria: * - parent refusal
comparison between erythromycin and neomycin treatment of hepatic encephalopathy

Conditions: Hepatic Encephalopathy; Hypertension, Portal; Liver Cirrhosis

Summary: comparison between the efficacy of two different antibiotics in patients with overt hepatic encephalopathy. the study is randomized, controlled and double-blinded.


Eligibility criteria:
inclusion criteria: * hepatic cirrhosis or portal hypertension * hepatic encephalopathy exclusion criteria: * acute liver failure * neuropsychiatric diseases * inflammatory bowel diseases * intestinal obstruction * shock * renal insufficiency * alcoholic hepatitis * alcohol abuse * antibiotic premedication

Keywords: hepatic encephalopathy hypertension, portal liver cirrhosis bacterial overgrowth syndrome
leveraging home health aides to improve outcomes in heart failure

Conditions: Heart Failure; Congestive Heart Failure

Summary: the purpose of the study is to determine the effectiveness of an intervention among home health aides caring for adults admitted to home care with a primary diagnosis of heart failure at vns health partners in care (home care agency). the study will examine the interventions' effect on home health aides' heart failure knowledge and confidence caring for adults with heart failure, as well as on the client's overall health (visits to the emergency department and hospital readmissions).

the investigator's central hypothesis is that an intervention that can optimize and improve the experience of home health aides caring for the heart failure patients has the potential to improve home health aides' own self-efficacy, heart failure knowledge, and also patient outcomes. the intervention for home health aides is comprised of a) remote classroom education on heart failure and b) an mhealth app containing hf educational content and a messaging application that connects hhas and their nurse supervisors. this intervention requires feasibility and acceptability testing, as well as preliminary testing of its effectiveness among home health aides caring for community-dwelling adults with heart failure.

Eligibility criteria:
inclusion criteria: * home health aide employed at vns health partners in care home care agency. * 1 or more years of experience as a home health aide. * speak english or spanish. * assigned to care for an adult admitted to home care with a primary diagnosis of heart failure. exclusion criteria: * doesn't meet inclusion criteria.

Keywords: home health aides home health care home care agency
safety study of shenmai(a chinese medicine injection) used in hospitals in china

Conditions: Shock; Coronary Heart Disease

Summary: the purpose of this study is to make a cohort event monitoring to see whether and how shenmai injection in hospital results in adverse events or adverse drug reactions.

safety surveillance on chinese medicine injection is an important problem that needs to be sorted out ,because in mainland china hospitals ,chinese medicine injection are used widely. population for taking medicine characteristics,the incidence rate of adr and other uncertain factors influence can not be found now. a registry study for shenmai injection safety surveillance with 30000 patients will be conducted from jan.2012 to dec.2015. eligibility criteria patients who will use shenmai injection in selected hospitals.

Eligibility criteria:
inclusion criteria: * all inpatients use shenmai injection in 30 selected hospitals during their hospital stay exclusion criteria: * none